uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Часто задаваемые вопросы
В каком секторе работает uniQure N.V (QURE)?
uniQure N.V относится к сектору Здравоохранение.
Какова текущая цена акций uniQure N.V (QURE)?
По последним данным, цена акций uniQure N.V составляет 45,04 $, предыдущее закрытие — 46,00 $. За последнюю торговую сессию акции uniQure N.V снизились на -0,96 $, что соответствует падению на -2,09%.
Выплачивает ли uniQure N.V (QURE) дивиденды?
Нет, uniQure N.V не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у uniQure N.V (QURE)?
У компании uniQure N.V бета 0.903, что означает, что её волатильность примерно соответствует рыночной.
